• Molecular NameDinoprostone
  • SynonymDinoprostone Prostaglandin E2; PGE2; Prostaglandin E2
  • Weight352.471
  • Drugbank_IDDB00917
  • ACS_NO363-24-6
  • Show 2D model
  • LogP (experiment)2.82
  • LogP (predicted, AB/LogP v2.0)2.62
  • pkaN/A
  • LogD (pH=7, predicted)0.51
  • Solubility (experiment)0.0581 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.66
  • LogSw (predicted, AB/LogsW2.0)2.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.5
  • No.of HBond Donors3
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds12
  • TPSA94.83
  • StatusFDA approved
  • AdministrationN/A
  • Pharmacologydinoprostone can be used as an abortifacient. It is a direct vasodilator, relaxing smooth muscles, and it inhibits the release of noradrenaline from sympathetic nerve terminals. It does not inhibit platelet aggregation, where PGI2 does.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding73.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmRapid metabolism of dinoprostone occurs primarily in the local tissues; any systemic absorption of the medication is cleared mainly in the maternal lungs and, secondarily, at sites such as the liver and kidneys.
  • Half life< 5 min
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50 = 500 mg/kg
  • LD50 (mouse)LD50 = 750 mg/kg